Iran will start domestic manufacture of Glatiramer acetate, which is used as a treatment for multiple sclerosis, General Director of Iranian "Tofik Daru" research company Huseyn Attar said, IRIB News reported.

Glatiramer acetate is an immunomodulator drug currently used to treat multiple sclerosis.

Although the clinical definition of multiple sclerosis requires two or more episodes of symptoms and signs, glatiramer acetate is approved for treatment after single episodes. It is also used to treat relapsing-remitting multiple sclerosis. It is administered by subcutaneous injection.
...

SonoSite, Inc., the world leader and specialist in bedside and point-of-care ultrasound, today announced a partnership with the African Institute of Innovation and Technology (AIIT), a Kenyan education trust, to establish the first ultrasound education program at Great Lakes University of Kisumu-a technology hub of East Africa. The AIIT ultrasound program is designed to provide physicians, midwives and clinical workers with greater access to ultrasound education, training, and medical resources to improve the health and welfare"...

Results show that for patients with uncontrolled blood pressure (BP) on renin angiotensin system (RAS) inhibitor monotherapy, switching to TWNYSTA® may:1

• deliver the blood pressure reductions needed to get them to BP goal
• demonstrate a rapid benefit, with over half of patients reaching office BP goal within 4 weeks and nearly 70% of patients within 12 weeks
• provide a safe and well-tolerated treatment option in this patient population

...

Quintiles, the world’s leading global biopharmaceutical services company, today announced the appointment of Tom Pike as chief executive officer. This appointment is part of the company’s long-term succession planning. Dennis Gillings, CBE, who founded the company, continues as executive chairman of its Board of Directors. Pike joins Quintiles on April 30, 2012.

“Tom"...

About 75 percent of malignant and benign blood cancers as well as genetic and metabolic disease are being treated through cellular grafting in Iran.

"Seventy five percent of malignant and benign blood cancers and genetic and metabolic disease are curable through cellular grafting," according to Dr. Ardeshir Qavamzadeh.

Qavamzadeh made the announcement as the Iranian Society of Pediatric Hamatology and Oncology is set to host the 11th Iranian Congress of Medical Oncology and Hematology. Qavamzadeh is the secretary of the congress.

Specialists from the United States, Canada,...

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) and Forest Laboratories, Inc. (NYSE: FRX) today announced that the U.S. Food and Drug Administration (FDA) notified the companies that it will require a three-month extension to complete its review of the data supporting the New Drug Application (NDA) for linaclotide for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic constipation (CC).

An"...

Sign Against Stroke Campaign launched at World Heart Federation’s World Congress of Cardiology; calls for 1.7 million voices to unite to improve the care and treatment of atrial fibrillation, which increases stroke risk by 500 percent

World Heart Federation, World Congress of Cardiology Scientific Sessions 2012 - April 23, 2012 :Seventy patient and professional organisations"...

Also announced - new head-to-head trials, LUX-Lung 7 and LUX-Lung 8, initiated to further evaluate afatinib in non-small cell lung cancer (NSCLC)

FOR NON-US MEDIA ONLY

Highly anticipated results from LUX-Lung 3, the pivotal Phase III lung cancer trial investigating Boehringer Ingelheim's front running oncology investigational compound, the ErbB Family Blocker afatinib, in patients with EGFR mutations, will be presented at the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago from 1 - 5 June 2012. LUX-Lung 3, which compares afatinib to standard platinum based"......

For Non-US, Non-UK & Non-Canadian Media Only

Boehringer Ingelheim announced today the launch of the GLORIATM-AF Registry Program, which is set to become the largest worldwide registry with the aim of understanding the long-term use of oral antithrombotic therapy in the prevention of non-valvular atrial fibrillation (AF)-related stroke in a real-world setting.

...